Clinical Trials Sponsored by The Medicines Company

Total 2302 results

The Medicines Company

Completed

A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Acute Bacterial Skin and Skin Structure Infection

United States
The Medicines Company

Completed

Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol (ORION-11)

Risk Factor, Cardiovascular | Elevated Cholesterol | ASCVD

Germany, Czechia, Hungary, Poland, South Africa, Ukraine, United Kingdom
The Medicines Company

Completed

A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (ORION-2)

Homozygous Familial Hypercholesterolemia

United States, Netherlands, South Africa
The Medicines Company

Completed

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) (ORION-1)

Diabetes | Familial Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

Canada, Netherlands, United States, United Kingdom, Germany
The Medicines Company

Terminated

Bivalirudin Infusion for Ventricular Infarction Limitation (BIVAL)

Acute Myocardial Infarction

Netherlands, France
The Medicines Company

Terminated

Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery

Bleeding

Germany, Switzerland
The Medicines Company

Completed

Cangrelor Prasugrel Transition Study

Coronary Artery Disease

United States
The Medicines Company

Completed

Clevidipine Bolus Administration in the Treatment of Hypertensive Patients Undergoing Cardiac Surgery (SPRINT) (SPRINT)

Hypertension

United States
The Medicines Company

Completed

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1) (ESCAPE-1)

Hypertension

United States
The Medicines Company

Completed

Cangrelor Ticagrelor Transition Study

Coronary Artery Disease

United States
The Medicines Company

Terminated

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. (Platform)

Atherosclerosis | Acute Coronary Syndrome (ACS)

United States
The Medicines Company

Completed

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

Healthy

United States
The Medicines Company

Completed

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB (HIT/TS)

Cardiovascular Disease | Coronary Artery Bypass Surgery

United States
The Medicines Company

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers

Healthy

United States
The Medicines Company

Withdrawn

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

Heparin-Induced Thrombocytopenia | Heparin-induced Thrombocytopenia and Thrombosis Syndrome

United States
The Medicines Company

Withdrawn

Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF (PRONTO II)

Hypertension | Dyspnea | Acute Heart Failure

United States
The Medicines Company

Completed

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

Thrombosis | Thrombocytopenia | Cardiac Disease | Coronary Artery Bypass Surgery

United States
The Medicines Company

Withdrawn

Association Between Patients' Perceptions of Success in Post-op Pain Management and Overall Experience With Care

Postoperative Pain

United States
The Medicines Company

Terminated

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial (ENDOMAX)

Bleeding | Peripheral Endovascular Interventions

United States
The Medicines Company

Completed

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO) (PRONTO)

Heart Failure | Hypertension

United States, Germany, France
The Medicines Company

Completed

Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY) (VELOCITY)

Hypertension

United States
The Medicines Company

Completed

Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2) (ESCAPE-2)

Hypertension

United States
The Medicines Company

Completed

Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG) (ECLIPSE-NTG)

Hypertension

United States
The Medicines Company

Completed

Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC) (ECLIPSE-NIC)

Hypertension

United States
The Medicines Company

Completed

Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP) (ECLISPE-SNP)

Hypertension

United States
The Medicines Company

Completed

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) (CHAMPION)

Atherosclerosis | Acute Coronary Syndrome | Percutaneous Coronary Intervention

United States
The Medicines Company

Completed

Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)

Cardiovascular Disease | Coronary Artery Bypass Surgery

United States
The Medicines Company

Completed

Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB (OPCAB)

Cardiac Surgery | Coronary Artery Bypass Surgery

United States
The Medicines Company

Completed

Bivalirudin as a Procedural Anticoagulant in Pediatrics

Cardiology
The Medicines Company

Completed

Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)

Thrombosis | Heparin-Induced Thrombocytopenia

United States
The Medicines Company

Completed

Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)

Myocardial Infarction | Acute Disease | Unstable Angina

United States
The Medicines Company

Completed

Study Of Angiomax In Infants Under Six Months With Thrombosis

Thrombosis

United States
The Medicines Company

Completed

Safety of Either a Single or Two Intravenous Doses of Orbactiv in Participants With Acute Bacterial Skin and Skin Structure Infection

Skin Diseases, Bacterial

United States
The Medicines Company

Completed

Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) (ORION-9)

Elevated Cholesterol | Heterozygous Familial Hypercholesterolemia

United States, Canada, Czechia, Denmark, Netherlands, South Africa, Spain, Sweden
The Medicines Company

Completed

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol (ORION-10)

Elevated Cholesterol | ASCVD

United States
The Medicines Company

Completed

Cangrelor to Clopidogrel or Prasugrel Transition Study (BRIDGE)

Coronary Artery Disease (CAD)

United States
The Medicines Company

Completed

A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)

Renal Impairment

New Zealand
The Medicines Company

Completed

Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation (AMPHORE)

Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

France
The Medicines Company

Completed

Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy (ABP-700)

Colonoscopy

Netherlands
The Medicines Company

Completed

Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH (BRAVO 2/3)

Transcatheter Aortic Valve Replacement | Aortic Valve Replacement | Severe Aortic Stenosis

Netherlands, Germany, United Kingdom, Canada, France, Italy, Switzerland
The Medicines Company

Completed

European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial (EUROMAX)

Acute Coronary Syndrome

Denmark, Netherlands, Italy, France, Germany, Poland, Austria, Czech Republic, Slovenia
The Medicines Company

Completed

Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE) (ACCELERATE)

Hypertension | Hemorrhage

United States, Germany
The Medicines Company

Terminated

A Clinical Trial to Demonstrate the Efficacy of Cangrelor (PCI)

Myocardial Infarction (MI) | Acute Coronary Syndromes (ACS)

United States
The Medicines Company

Completed

Maintenance of Platelet Inhibition With Cangrelor (Bridge)

Acute Coronary Syndrome (ACS)

United States
The Medicines Company

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDCO-2010 in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery

Cardiopulmonary Bypass | Coronary Artery Bypass Graft
The Medicines Company

Completed

Utilisation of Angiox® in European Practice (EURO-vision)

Stable Angina (SA) | NSTE-ACS (NSTEMI and UA) | STEMI (STE-ACS)

France, Germany
The Medicines Company

Completed

Pharmacokinetics/Pharmacodynamics (PK/PD) of Cangrelor

Healthy

United States
The Medicines Company

Completed

Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI

Myocardial Infarction

United States
The Medicines Company
The Cleveland Clinic

Completed

MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial (PILOT)

Acute Coronary Syndrome

Poland, Netherlands, Hungary, Canada, Czechia
Columbia University
The Medicines Company

Withdrawn

The Effect of Clevidipine on Intracranial Pressure and Cerebral Perfusion Pressure (CCP) in Brain Injured Patients

Hypertension

3

Subscribe